RecruitingNCT07026591

Epilepsy and Driving


Sponsor

Fondation Ophtalmologique Adolphe de Rothschild

Enrollment

40 participants

Start Date

Nov 6, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Epilepsy can lead to cognitive impairments, particularly in attention, which may affect daily activities such as driving. Driving plays a key role in maintaining autonomy and is essential for the social and professional integration of people with epilepsy. Therefore, assessing fitness to drive is a major issue for individuals with epilepsy. French legislation governing driving for people with epilepsy clearly outlines the periods during which a person is not permitted to drive. However, the means or methods for evaluating driving fitness in these individuals are not well defined. Currently, assessment is based more on a medical consultation than on a comprehensive evaluation of driving ability. Using a driving simulator in combination with an EEG could be a valuable approach to better assess the impact of epilepsy-related cognitive impairments on driving performance.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria6

  • Aged between 18 and 65 years
  • Holder of a category B driving license
  • Active driver: drives at least once a month
  • No medical condition contraindicating driving, except for epilepsy
  • Provides explicit consent to participate in the study
  • Affiliated with or a beneficiary of a social security scheme

Exclusion Criteria3

  • Subject to legal protection (guardianship and curatorship are accepted for individuals with epilepsy, as this population represents a significant proportion of our institution's patients)
  • Pregnant or breastfeeding women
  • Known cybersickness (virtual reality or simulator sickness)

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Institut La Teppe

Tain-l'Hermitage, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07026591


Related Trials